One large meta-analysis involving 16 trials and 6,208 patients reported an incidence of 4% for any pulmonary toxicity and 1.5% for high-grade pneumonitis, which appeared similar across PD-1 and PD-L1 inhibitors (Sun et al., 2019). This evidence concerns the gene CD274 and pneumonitis.